Complete and durable tumor regression occurred with Iadademstat–induced NOTCH activation in a chemoresistant PDX model. Further supports LSD1 inhibitors as a possible new and targeted therapy for SC...
Read moreCombining immunotherapy with chemotherapy in patients with metastatic squamous cell carcinoma "significantly increases" the survival of patients, write the authors in The New England Journal of Medici...
Read moreThe study, named CLEPSIDRA, will be conducted in several Spanish hospitals . CLEPSIDRA is a single - arm, open - label study of Iadademstat in combination with the standard of care treatment p latinum...
Read moreResearchers from the Genes and Cancer research group at the Bellvitge Biomedical Research Institute (IDIBELL) have identified inactivating mutations in a number of genes that code for HLA-I histocompa...
Read moreResearchers from the UAB, the CVC and the Hospital de Bellvitge - Idibell have developed a technology for biopsies which can navigate through a patient's airways following a ready-planned and localise...
Read moreThe milestone payment is the first from the licensing agreement between the two companies. Under the terms of that agreement, which was signed in September 2015, Novartis has exclusive development and...
Read moreResearchers at the Bellvitge Biomedical Research Institute (IDIBELL), led by Dr. Montse Sanchez-Cespedes, have demonstrated in in vitro and in vivo studies the effectiveness of a new drug combination ...
Read moreCollaboration boosts development of a fully differentiated inhibitor of the PI3K/Akt/mTOR pathway. ABTL0812 is currently in Phase 2 clinical trials to treat lung and endometrial cancers.
Read moreThe research work led by CIMA has identified a molecule, called TMPRSS4, which acts as a biomarker for the prognosis of lung cancer. "By means of complex technological systems called "microarrays" and...
Read moreThe specific combination of the drugs dasatinib and demcizumab impairs the growth of KRAS-driven lung tumours, the most aggressive sub-type and with the lowest survival rates
Read moreThis study goes a step further and investigates nintedanib* effectiveness in squamous cell carcinoma, so it will use new preclinical cell crops models, unique in Spain, that allow interaction between ...
Read moreUnder the terms of the agreement Novartis will acquire exclusive global rights to develop, manufacture and commercialize Palobiofarma´s adenosine A2Areceptor antagonist PBF-509, currently entering Ph...
Read more